| Literature DB >> 23375629 |
Erin A Bohula May1, David Faxon.
Abstract
Despite the poor prognosis associated with severe, symptomatic aortic stenosis, treatment options were limited for a large subgroup of patients deemed high risk for surgical replacement. The introduction of transcatheter aortic valve replacement (TAVR) over the past 10 years marks a new and exciting era in the treatment of valvular disease in these high-risk and inoperable patients. In this review, we outline the historical development, key clinical trials, current outcomes and future directions of TAVR. Published by Elsevier Inc.Entities:
Mesh:
Year: 2013 PMID: 23375629 DOI: 10.1016/j.tcm.2012.11.001
Source DB: PubMed Journal: Trends Cardiovasc Med ISSN: 1050-1738 Impact factor: 6.677